Reinterpreting anomalous competitive binding experiments within G protein-coupled receptor homodimers using a dimer receptor model-Reference-Cited by-同舟云学术

Reinterpreting anomalous competitive binding experiments within G protein-coupled receptor homodimers using a dimer receptor model

Published:2019-01 Issue: Volume:139 Page:337-347
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Casadó-Anguera Verònica^ORCID,Moreno Estefanía^ORCID,Mallol Josefa^ORCID,Ferré Sergi^ORCID,Canela Enric I.^ORCID,Cortés Antoni^ORCID,Casadó Vicent^ORCID

Funder

“Ministerio de Economía y Competitividad”

European Regional Development Funds of the European Union

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas

“Fundació La Marató de TV3”

Generalitat de Catalunya

Publisher

Elsevier BV

Subject

Pharmacology

Reference100 articles.

1. Structure-based sequence alignment of the transmembrane domains of all human GPCRs: phylogenetic, structural and functional implications;Cvicek;PLoS Comput. Biol.,2016

2. Allosteric modulators of G protein-coupled receptors;Wells;Curr. Top. Med. Chem.,2014

3. Historical review: a brief history and personal retrospective of seven-transmembrane receptors;Lefkowitz;Trends Pharmacol. Sci.,2004

4. Are GPCRs still a source of new targets?;Garland;J. Biomol. Screen.,2013

5. Structure-function of the G protein-coupled receptor superfamily;Katritch;Annu. Rev. Pharmacol. Toxicol.,2013

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring GPCR conformational dynamics using single-molecule fluorescence;Methods;2024-06

2. GPCR heteromers: An overview of their classification, function and physiological relevance;Frontiers in Endocrinology;2022-08-30

3. Preferential Gs protein coupling of the galanin Gal1 receptor in the µ-opioid-Gal1 receptor heterotetramer;Pharmacological Research;2022-08

4. Unmasking allosteric-binding sites: novel targets for GPCR drug discovery;Expert Opinion on Drug Discovery;2022-06-13

5. Non-Peptide Opioids Differ in Effects on Mu-Opioid (MOP) and Serotonin 1A (5-HT1A) Receptors Heterodimerization and Cellular Effectors (Ca2+, ERK1/2 and p38) Activation;Molecules;2022-04-06